GlassScriptPhysician profile
Hal S Shimazu
NPI 1073682241
$7,998.16
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,372 · 2020: $1,548 · 2021: $1,772 · 2022: $1,505 · 2023: $1,559 · 2024: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $962.44 | 2019-2024 | Otezla, Repatha, Prolia |
| Abbvie INC. | $828.78 | 2019-2024 | Vraylar, Ubrelvy, Synthroid |
| Astrazeneca Pharmaceuticals LP | $641.36 | 2019-2024 | Airsupra, Farxiga |
| Lilly USA, LLC | $602.51 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $488.10 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $484.43 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $407.56 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $393.39 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $300.29 | 2021-2023 | |
| Glaxosmithkline, LLC. | $259.28 | 2019-2023 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $247.43 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $226.41 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Astellas Pharma US INC | $213.87 | 2019-2023 | Veozah |
| Allergan, INC. | $197.40 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $181.05 | 2021-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hal Shimazu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.